Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03411187
Other study ID # exhaust
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date January 1, 2018
Est. completion date December 30, 2018

Study information

Verified date September 2018
Source Fujian Medical University
Contact Wen-xin ZHAO, MD
Phone 8613365910359
Email zhaowx@fjmu.edu.cn
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Endoscopic thyroidectomy developed rapidly in recent years, and the most popular surgical approach was endoscopic thyroidectomy by bilateral areola approach, but some operative steps was required optimization. One of the most annoying problem was the smog blurring endoscopic lens during surgery. The researcher summarized a set of convenient foot-control exhaust method and carried out this prospective study.


Description:

The patients with papillary thyroid microcarcinoma were included according to the inclusive criteria and randomly divided them into two groups (foot-control exhaust group and direct exhaust group). The foot-control exhaust group used the foot-control exhaust method by the way of adjustable Pressure to intermittent exhaust, while direct exhaust group exhaust through the Trocar hole. Comparison of operation time, times of wiping the endoscopic lens, volume of postoperative drainage, and number of identified parathyroid gland between two groups.


Recruitment information / eligibility

Status Recruiting
Enrollment 100
Est. completion date December 30, 2018
Est. primary completion date June 30, 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria:

1. Patients with maximum tumor diameter =1 cm;

2. patients without lateral neck lymph node metastases;

3. patients without distant metastases;

4. patients who only needed unilateral surgery following the guidelines;

5. patients with strong cosmetic requirement.

Exclusion criteria:

1. Patients with maximum tumor diameter >1 cm;

2. patients who needed complement total thyroidectomy according to the guidelines, including tumor extrathyroidal extension as well as large amount of neck lymph node metastases and distant metastases;

3. patients without cosmetic requirements.

Study Design


Intervention

Device:
used of the Pressure adjustable foot-control method
Whether The Pressure adjustable foot-control method is used.
direct exhaust
direct exhaust through the trocar.

Locations

Country Name City State
China Wen-xin ZHAO Fuzhou Fujian

Sponsors (1)

Lead Sponsor Collaborator
Bo Wang,MD

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Flap separation time Flap separation time was acquired from endoscopic video was the period from endoscopy into the body to building up operation space. 1 day after surgery
Primary Glandular excision time Glandular excision time was defined from incising cervical white line to removing Berry ligament. 1 day after surgery
Primary Central lymph node dissection time Central lymph node dissection time: was from separating central lymph node to the specimen removed. 1 day after surgery
Secondary Times of wiping lens Times of wiping lens calculated from endoscopic video after operation was defined the times of wiping lens from endoscopy into the body to central lymph node removed. 1 day after surgery
Secondary Volume of intraoperative blood loss Volume of intraoperative blood loss was estimated the volume of intraoperative blood loss. 1 day after surgery
Secondary Volume of Postoperative drainage Volume of Postoperative drainage was accurately calculated the total volume while the drainage tube removed after operation. 1 day,2 day,3 day after surgery
Secondary The number of identifying parathyroid glands The number of identifying parathyroid glands was evaluated at postoperation while parathyroid glands was identified during surgery. 1 day after surgery
Secondary Blood PTH level measurement of PTH level in blood preoperative, first day after operation, one week after surgery, two months after surgery.
Secondary Blood calcium level to measure the blood calcium level in the blood before surgery, the first day after surgery, one week after surgery, two months after surgery.
See also
  Status Clinical Trial Phase
Recruiting NCT05774535 - Prospective, Observational Study on the Carotid Intima-media Thickness in Patients Undergoing Thyroid Surgery
Withdrawn NCT04224792 - Effects of Exercise Training on Fatigue in Thyroid Cancer Survivors N/A
Completed NCT01728623 - A Study of E7080 in Subjects With Advanced Thyroid Cancer Phase 2
Recruiting NCT03175224 - APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors Phase 2
Completed NCT02911155 - Cancer and Other Disease Risks in U.S. Nuclear Medicine Technologists
Recruiting NCT05025046 - NGS-based Thyroscan Genomic Classifier in the Diagnosis of Thyroid Nodules
Not yet recruiting NCT03978351 - The Role of Midkine in Diagnosis of Thyroid Cancer
Completed NCT02658513 - Evaluation of Lancet Blood Sampling for Radioiodine Dosimetry in Thyroid Cancer
Terminated NCT02628535 - Safety Study of MGD009 in B7-H3-expressing Tumors Phase 1
Completed NCT02375451 - Effect of Childhood Radioiodine Therapy on Salivary Function N/A
Withdrawn NCT01994200 - Developing and Implementing an Interdisciplinary Team-Based Care Approach (ITCA-ThyCa) for Thyroid Cancer Patients Phase 1/Phase 2
Terminated NCT01403324 - Comparison of Dosimetry After rhTSH or Withdrawal of Thyroid Hormone in Metastatic or Locally Advanced Thyroid Cancer N/A
Completed NCT00970359 - Reacquisition of Radioactive Iodine (RAI) Uptake of RAI-Refractory Metastatic Thyroid Cancers by Pretreatment With the Selective MEK Inhibitor AZD6244 N/A
Completed NCT00439478 - Dental Safety Profile of High-Dose Radioiodine Therapy Phase 4
Completed NCT00223158 - Evaluation Study of L-T3 Utility in the Follow-up of Patients With Thyroid Cancer N/A
Active, not recruiting NCT04544111 - PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer Phase 2
Completed NCT04876287 - Salivary dysfuncTion After Radioiodine Treatment
Recruiting NCT06073223 - Intervention to Decrease Overtreatment of Patients With Low-risk Thyroid Cancer N/A
Recruiting NCT06037174 - Comparison of Quality of Life in Patients With Differentiated Thyroid Carcinoma Undergoing Different Surgery
Recruiting NCT04952493 - Anlotinib or Penpulimab in Combination With RAI for DTC Phase 2